AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32006516 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR+V (combined measles-mumps-rubella-varicella vaccine)
Number of subjects: 0
Study 32006516 — intervention group
Group type: COMPARATOR
Intervention: Monovalent varicella vaccine
Number of subjects: 0
Study 35867273 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1–3 mg/kg/d, BID)
Number of subjects: 20
Study 35867273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35867273 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 34436610 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA plus ticagrelor
Number of subjects: 6558
Study 34436610 — intervention group
Group type: COMPARATOR
Intervention: ASA monotherapy
Number of subjects: 6558
Study 36115296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - 8 sessions of 90 minutes each
Number of subjects: 40
Study 36115296 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study 34114651 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate CASITA intervention
Number of subjects: 347
Study 34114651 — intervention group
Group type: COMPARATOR
Intervention: Delayed CASITA intervention
Number of subjects: 347
Study 96312189 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (6 mg i.m.)
Number of subjects: 6
Study 96312189 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (30 mg i.m.)
Number of subjects: 6
Study 96312189 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.3 mg)
Number of subjects: 6
Study 96312189 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (6 mg i.m.) at 120 mg/day morphine
Number of subjects: 6
Study 36223962 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy ad libitum diet with S&SE products
Number of subjects: 370
Study 36223962 — intervention group
Group type: COMPARATOR
Intervention: Healthy ad libitum diet without S&SE products
Number of subjects: 370
Study 32597466 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib plus hydroxychloroquine
Number of subjects: 15
Study 32810387 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer educational attainment
Number of subjects: 0
Study 32810387 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher math class taken
Number of subjects: 0
Study 32810387 — intervention group
Group type: EXPERIMENTAL
Intervention: Math ability, cognitive performance, and intelligence
Number of subjects: 0
Study 36101802 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall nursing intervention under the supervision of DSA
Number of subjects: 50
Study 36101802 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing intervention
Number of subjects: 50
Study 33866329 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary data‐based Mendelian randomization (SMR) method integrating GWAS and eQTL data
Number of subjects: 13
Study 33866329 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyzed version of the eQTL summary data in the brain (brain‐eMeta)
Number of subjects: 13
Study 33866329 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR analysis
Number of subjects: 13
Study 35991778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral ilioinguinal and iliohypogastric nerve block
Number of subjects: 64
Study 35991778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 64
Study 33316225 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground robotic (OR) training added to ongoing rehabilitation
Number of subjects: 36
Study 33316225 — intervention group
Group type: COMPARATOR
Intervention: Ongoing rehabilitation program (Control Group)
Number of subjects: 36
Study 32989447 — intervention group
Group type: EXPERIMENTAL
Intervention: IV mecillinam
Number of subjects: 1129
Study 32989447 — intervention group
Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 1129
Study 32989447 — intervention group
Group type: COMPARATOR
Intervention: meropenem
Number of subjects: 1129
Study 32146983 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound Tracker Professional iOS compatible device
Number of subjects: 20
Study 32146983 — intervention group
Group type: COMPARATOR
Intervention: Acetate tracing
Number of subjects: 20
Study 32146983 — intervention group
Group type: COMPARATOR
Intervention: Aranz medical wound measuring system
Number of subjects: 20
Study 35475793 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment for 3 consecutive weeks based on routine conventional treatment
Number of subjects: 80
Study 35475793 — intervention group
Group type: COMPARATOR
Intervention: Routine conventional treatment alone
Number of subjects: 80
Study 32864685 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week)
Number of subjects: 851
Study 32864685 — intervention group
Group type: COMPARATOR
Intervention: MTX (20 mg/week)
Number of subjects: 851
Study 32864685 — intervention group
Group type: EXPERIMENTAL
Intervention: PASDAS (continuous composite measure)
Number of subjects: 851
Study 32864685 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous composite measures (DAS28-CRP, CDAI, SDAI, DAPSA, PASDAS)
Number of subjects: 851
Study 32453997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training session with body weight support (BWS)
Number of subjects: 0
Study 32453997 — intervention group
Group type: COMPARATOR
Intervention: Gait training using a walker without BWS
Number of subjects: 0
Study 32638063 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 12 weeks
Number of subjects: 79
Study 32638063 — intervention group
Group type: COMPARATOR
Intervention: PFMT plus solifenacin for 36 weeks
Number of subjects: 79
Study 32638063 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 79
Study 32638063 — intervention group
Group type: COMPARATOR
Intervention: PFMT plus solifenacin
Number of subjects: 79
Study 32497454 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (10 X 1-min bouts of running at 80-90% HRmax, separated by 1-min active recovery)
Number of subjects: 24
Study 32497454 — intervention group
Group type: COMPARATOR
Intervention: MICT (50-min continuous jogging/brisk walking at 65-70% HRmax)
Number of subjects: 24
Study 32497454 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 24
Study 32497454 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 24
Study 32497454 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT and MICT
Number of subjects: 24
Study 34579020 — intervention group
Group type: EXPERIMENTAL
Intervention: CARET + broccoli supplement (TS)
Number of subjects: 44
Study 34579020 — intervention group
Group type: EXPERIMENTAL
Intervention: CARET + placebo (TP)
Number of subjects: 44
Study 34579020 — intervention group
Group type: COMPARATOR
Intervention: control + broccoli supplement (S)
Number of subjects: 44
Study 34579020 — intervention group
Group type: COMPARATOR
Intervention: control + placebo (CP)
Number of subjects: 44
Study 33980951 — intervention group
Group type: EXPERIMENTAL
Intervention: BLC (bioconverted product of Lotus corniculatus seed)
Number of subjects: 18
Study 33980951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32243385 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 32243385 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of granisetron (control)
Number of subjects: 0
Study 36167703 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline continuous theta‐burst transcranial magnetic stimulation (cTBS) of the DLPFC
Number of subjects: 30
Study 36167703 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 33907133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine
Number of subjects: 56
Study 33907133 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 56
Study 34193475 — intervention group
Group type: EXPERIMENTAL
Intervention: rfMDA using dihydroartemisinin-piperaquine (DP)
Number of subjects: 222
Study 34193475 — intervention group
Group type: COMPARATOR
Intervention: RACD involving RDTs and artemether-lumefantrine
Number of subjects: 222
Study 32144210 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural programme
Number of subjects: 0
Study 32144210 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35226724 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated boluses (ropivacaine 0.2% as 8 ml every 2 h, initiated 5 h after discharge)
Number of subjects: 70
Study 35226724 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (ropivacaine 0.2% as 6 ml/h, initiated before discharge)
Number of subjects: 70
Study 35226724 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated boluses
Number of subjects: 70
Study 35226724 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 70
Study 32584881 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation from mid-gestation to term
Number of subjects: 236
Study 32584881 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation from pre-conception to term
Number of subjects: 236
Study 32584881 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented mothers
Number of subjects: 236
Study 34246358 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (3 µg inactivated SARS-CoV-2 virion) administered intramuscularly on days 0 and 14
Number of subjects: 10218
Study 34246358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (all vaccine components except inactivated virus)
Number of subjects: 10218
Study 34246358 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine
Number of subjects: 10218
Study 34246358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10218
Study 36056778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (25 mg orally twice daily in continuous 28-day cycles)
Number of subjects: 12
Study 33808476 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented Mediterranean Diet (SMD) with 50 g/day of extra-virgin olive oil (EVOO) and 30 g/day of walnuts
Number of subjects: 102
Study 33808476 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented Mediterranean Diet (SMD)
Number of subjects: 102
Study 33808476 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (control group)
Number of subjects: 102
Study 33105861 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudzu flower and mandarin peel extract (KM) 1150 mg/day
Number of subjects: 84
Study 33105861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 35368058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg biweekly for 52 weeks)
Number of subjects: 300
Study 35368058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 35368058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 300
Study 33323690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0
Study 33323690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32434975 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release drugs - chlorhexidine gel
Number of subjects: 60
Study 32434975 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 60
Study 32434975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibers
Number of subjects: 60
Study 33579349 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Banxia Xiexin decoction (BXD) for 3 weeks
Number of subjects: 84
Study 33579349 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study 34797698 — intervention group
Group type: COMPARATOR
Intervention: 35% phosphoric acid
Number of subjects: 81
Study 34797698 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (200 mJ, 30 Hz)
Number of subjects: 81
Study 34797698 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (250 mJ, 30 Hz)
Number of subjects: 81
Study 34918443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg.kg-1)
Number of subjects: 53
Study 34918443 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg.kg-1)
Number of subjects: 53
Study 32333434 — intervention group
Group type: EXPERIMENTAL
Intervention: Televised alcohol advertising exposure
Number of subjects: 54671
Study 35789991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 international units monthly for 5 years)
Number of subjects: 20334
Study 35789991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 international units monthly for 5 years) in adults aged ≥70 years
Number of subjects: 20334
Study 33372392 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU and Calcium 1000 mg daily for 6 weeks (Group A)
Number of subjects: 70
Study 33372392 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D 250 IU and Calcium 500 mg daily for 6 weeks (Group B)
Number of subjects: 70
Study 33372392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 32414298 — intervention group
Group type: COMPARATOR
Intervention: 100% adherence to placebo
Number of subjects: 0
Study 32414298 — intervention group
Group type: COMPARATOR
Intervention: 0% adherence to placebo
Number of subjects: 0
Study 34496115 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant center-based outreach intervention
Number of subjects: 103
Study 35074134 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Number of subjects: 0
Study 35074134 — intervention group
Group type: COMPARATOR
Intervention: Immediate umbilical cord clamping
Number of subjects: 0
Study 32739569 — intervention group
Group type: EXPERIMENTAL
Intervention: Live phone call primer
Number of subjects: 2825
Study 32739569 — intervention group
Group type: COMPARATOR
Intervention: Text message primer
Number of subjects: 2825
Study 32525863 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense enteral nutrition (1.5kcal/mL)
Number of subjects: 1257
Study 32525863 — intervention group
Group type: COMPARATOR
Intervention: Routine enteral nutrition (1kcal/mL)
Number of subjects: 1257
Study 35801864 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-Minute Walk Test
Number of subjects: 67
Study 35801864 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bruce Treadmill Test
Number of subjects: 67
Study 32501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for type 2 diabetes (specific treatments not detailed)
Number of subjects: 515
Study 32501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HbA1c
Number of subjects: 515
Study 32501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in systolic blood pressure
Number of subjects: 515
Study 32501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in diastolic blood pressure
Number of subjects: 515
Study 32501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microalbuminuria
Number of subjects: 515
Study 32501612 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 515
Study 35111219 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 36
Study 35111219 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 36
Study 33827832 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 weeks
Number of subjects: 2760
Study 33827832 — intervention group
Group type: COMPARATOR
Intervention: Expectant management until 42 weeks
Number of subjects: 2760
Study 32807214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin monotherapy
Number of subjects: 0
Study 32807214 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin followed by ciprofloxacin
Number of subjects: 0
Study 35113940 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based weight management programme for 12 weeks
Number of subjects: 739
Study 35113940 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based weight management programme for 52 weeks
Number of subjects: 739
Study 35113940 — intervention group
Group type: COMPARATOR
Intervention: Self-help
Number of subjects: 739
Study 32081633 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ligament (LockDown)
Number of subjects: 14
Study 32081633 — intervention group
Group type: COMPARATOR
Intervention: Coracoclavicular suspensory construct
Number of subjects: 14
Study 615920668 — intervention group
Group type: EXPERIMENTAL
Intervention: FrACT visual acuity testing system
Number of subjects: 25
Study 615920668 — intervention group
Group type: COMPARATOR
Intervention: ETDRS visual acuity testing system
Number of subjects: 25
Study 615920668 — intervention group
Group type: EXPERIMENTAL
Intervention: FrACT and ETDRS during defocus testing
Number of subjects: 25
Study 615920668 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS (0.02 logMAR) and FrACT (0.03 logMAR)
Number of subjects: 25
Study 35368961 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Pingsou Decoction combined with azithromycin
Number of subjects: 68
Study 35368961 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 68
Study 34003667 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg followed by 0.5 mg 1 hour later)
Number of subjects: 75
Study 34003667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 34003667 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 75
Study 32926841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m2 intravenously every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor)
Number of subjects: 255
Study 32926841 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone or Enzalutamide (1000 mg orally once daily plus 5 mg prednisone twice daily or 160 mg orally daily)
Number of subjects: 255
Study 32926841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 255
Study 32926841 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone or Enzalutamide
Number of subjects: 255
Study 35199913 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Singh's algorithm care bundle (MOSA)
Number of subjects: 22
Study 35199913 — intervention group
Group type: COMPARATOR
Intervention: Control group (professional judgments for decannulation)
Number of subjects: 22
Study 32299585 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent smokers
Number of subjects: 2564
Study 32299585 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 2564
Study 32715828 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 iStent® trabecular micro-bypass stents
Number of subjects: 39
Study 32223381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic BP-targets
Number of subjects: 13266
Study 32223381 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic BP-targets
Number of subjects: 13266
Study 36154510 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy healing
Number of subjects: 32
Study 36154510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 34023321 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic anticancer treatment (SACT)
Number of subjects: 280
Study 34023321 — intervention group
Group type: COMPARATOR
Intervention: No systemic anticancer treatment (SACT)
Number of subjects: 280
Study 34023321 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical pleurodesis
Number of subjects: 280
Study 34023321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological sensitivity
Number of subjects: 280
Study 35932165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 88
Study 35932165 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 88
Study 32307286 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan blood implant with microfracture
Number of subjects: 0
Study 32307286 — intervention group
Group type: COMPARATOR
Intervention: Microfracture alone
Number of subjects: 0
Study 33443368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training to failure (FAI)
Number of subjects: 41
Study 33443368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training to voluntary interruption (VOL)
Number of subjects: 41
Study 33443368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with fixed low repetitions (FIX)
Number of subjects: 41
Study 33446795 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling coffee aroma
Number of subjects: 0
Study 33446795 — intervention group
Group type: COMPARATOR
Intervention: Inhaling sham aroma
Number of subjects: 0
Study 33446795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessment using visual analog scale
Number of subjects: 0
Study 34874061 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE Cornerstone intervention (lay navigator-led telehealth sessions)
Number of subjects: 63
Study 34874061 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study 33726840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated 12-h night shift with total sleep deprivation
Number of subjects: 35
Study 33726840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated 12-h night shift with a 30-min nap opportunity
Number of subjects: 35
Study 33726840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated 12-h night shift with a 2-h nap opportunity
Number of subjects: 35
Study 36114096 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (100 mg/m² on days 1, 8, and 15 of a 21-day cycle)
Number of subjects: 503
Study 36114096 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (60 mg/m² on day 1)
Number of subjects: 503
Study 36114096 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 503
Study 36114096 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 503
Study 33657558 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fitting group (EF, n = 67)
Number of subjects: 127
Study 33657558 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 60)
Number of subjects: 127